Meta AnalysisID 2756
石杉碱甲治疗重度抑郁症：文献综述
CRD42015024796
The aim of this review is to evaluate the efficacy and safety of Huperzine A in the treatment of major depressive disorder (any diagnostic criteria).
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 2756
- Evidence Id
- 11314
- Core Evidence Id
- 11314
- Source Meta Analysis Id
- 2705
- Herb2 Meta Analysis Id
- HBMA002705
- Crd Id
- CRD42015024796
- Title
- Huperzine A for major depressive disorder: a review of the literature
- Review Question
- The aim of this review is to evaluate the efficacy and safety of Huperzine A in the treatment of major depressive disorder (any diagnostic criteria).
- Study Type Included
- Randomised controlled trials, open labels, case reports, and case series will be included.
- Condition Being Studied
- Huperzine A, an alkaloid initially identified from the Chinese herbal medicine Huperia serrata, is a potent reversible acetylcholinesterase (AChE) inhibitor and has been shown to have cognition-enhancing effects in animal models and patients with Alzheimer's disease and schizophrenia. We will evaluate the efficacy and safety of adjunctive Huperzine A in the treatment of major depressive disorder using any diagnostic criteria. There were no restrictions regarding language, sample size, or time period.
- Participant
- Patients using antidepressive drugs.
- Animal
- Human Disease Modelled
- Intervention
- Huperzine A plus antidepressive drugs.
- Comparator Control
- Antidepressive drugs plus placebo or antidepressive drugs monotherapy.
- Main Outcome
- Cognitive effect assessed by any instrument.
- Outcome Measure
- Additional Outcome
- 1) Changes in scores of Positive and Negative Syndrome Scale (PANSS) and the Brief Psychiatric Rating Scale Total (BPRS) total score from baseline to end of treatment. 2) Adverse events. 3) Discontinuation.
- Study Method
- Intervention, Systematic review
- Keyword
- Alkaloids; Depressive Disorder, Major; Humans; huperzine A; Sesquiterpenes
- Contact
- Wei Zheng [email protected]
- Organisational Affiliation
- Guangzhou Brain Hospital (Guangzhou Huiai Hospital), Affiliated Hospital of Guangzhou Medical University http://www.gzbrain.cn/
- Funding Source
- Other Selection Criteria
- Final Publication
- Shanghai Arch Psychiatry. 2016 Apr 25; 28(2): 64-71. doi: 10.11919/j.issn.1002-0829.216003.Huperzine A for treatment of cognitive impairment in major depressive disorder: a systematic review of randomized controlled trials. Zheng W, Xiang YQ, Ungvari GS, Chiu FK, H Ng C, Wang Y, Xiang YT.
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Completed published
- First Submission Date
- Registration Date
- 2015-07-23
- Anticipated Start Date
- 2015-02-01
- Anticipated Completion Date
- 2016-08-01
- Title Cn
- 石杉碱甲治疗重度抑郁症：文献综述
- Title En
- Huperzine A for major depressive disorder: a review of the literature
- Bilingual Status
- complete